The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trials Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in United States (U.S.) and investigators in LMICs. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. These partnerships are referred to as HIV-Associated Malignancy Research Centers (HAMRCs).
Each proposed U54 HAMRC should be based upon partnerships involving at least one U.S. institution and institutions from at least two or more LMICs. Each HAMRC application is required to propose between two and three research projects that address questions in one scientific theme (e.g., viral-associated cancers) that is relevant to HIV-associated malignancies in LMICs or the U.S. The proposed projects may range, as appropriate, from basic research to translational efforts as well as to population and implementation studies. Mechanistic clinical studies that meet NIH's definition of a clinical trial will be allowed. In addition, the proposed U54 HAMRC must include an Administrative Core and a Developmental Core.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- AIDS Application Due Date(s): March 30, 2022
RFA-CA-22-011 Expiration Date March 31, 2022
Applicants are required to use the multiple PD/PI option so that there is shared leadership for the U54 HAMRC by the U.S. and LMIC investigators. There must be at least one PD/PI at the US institution and at least one PD/PI at a LMIC institution.
All PDs/PIs must commit at least 1.2 person-months to the U54 HAMRC.
The primary appointment of the individual designated as contact PD/PI must be at the institution submitting the application.
All individuals designated as PDs/PIs must have expertise in HIV/AIDS, oncology or implementation research and the appropriate level of authority and seniority to direct the U54 HAMRC.
Individuals designated as the PDs/PIs are also expected to have a history of prior scientific and/or administrative collaborations relevant to the goals of this FOA.